Overview

Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan

Status:
Not yet recruiting

Trial end date:
2027-07-30

Target enrollment:

Participant gender:

Summary

This is a multicenter, randomized, double-blind, placebo-controlled study to assess whether trilaciclib administered prior to topotecan is non-inferior to placebo administered prior to topotecan with regard to overall survival.

Phase:

Phase 4

Details

Lead Sponsor:

G1 Therapeutics, Inc.

Treatments:

Topotecan